A recently completed trial at the Massachusetts General Hospital Cancer Centre in Boston indicates that next-generation sequencing (NLS) conducted on biopsy specimens of 5,954 patients "with relapsed, refractory advanced cancers permits training of newly one-with (18%) of patients to evidence-based investigational therapy." Known as NCI-MATCH (National Cancer Institute Molecular Analysis for Therapy Choice), this was the first national trial of its kind in the United States, incorporating "centralized diagnostic testing and geographically distributed clinical investigation of dozens of parallel treatment options."
To read more about this trial, click here
Source mentioned: Flaherty KT, Gray RJ, Chen AP, et al. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). JCO; Published online 13 October 2020. DOI: 10.1200/JCO.19.03010.
No comments:
Post a Comment